Thomas Edward Hamilton - 16 Feb 2024 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role
Director
Signature
/s/ Jennifer Johansson, Attorney-in-fact
Issuer symbol
LRMR
Transactions as of
16 Feb 2024
Net transactions value
+$499,998
Form type
4
Filing time
31 May 2024, 16:56:58 UTC
Previous filing
19 May 2023
Next filing
17 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LRMR Common Stock Purchase $499,998 +57,208 +11% $8.74 564,798 16 Feb 2024 Direct F1
holding LRMR Common Stock 159,433 16 Feb 2024 Post Edison, LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LRMR Stock Option (Right to Buy) Award $0 +19,000 $0.000000 19,000 29 May 2024 Common Stock 19,000 $7.07 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. (the "Company") at the offering price, which closed on February 16, 2024.
F2 The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.